Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
OCD
MCID: OBS002
MIFTS: 69

Obsessive-Compulsive Disorder (OCD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Obsessive-Compulsive Disorder

About this section

MalaCards integrated aliases for Obsessive-Compulsive Disorder:

Name: Obsessive-Compulsive Disorder 57 12 25 37 29 55 43 44 15 63 73
Ocd 57 76 25
Obsessive-Compulsive Disorder, Susceptibility to 57 6
Obsessive Compulsive Disorder 12 40
Anancastic Neurosis 12 25
Obsessive-Compulsive Neurosis 25
Obsessive Compulsive Behavior 73
Obsessivecompulsive Disorder 76
Anankastic Neurosis 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant form


HPO:

32
obsessive-compulsive disorder:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

OMIM 57 164230
Disease Ontology 12 DOID:10933
ICD10 33 F42 F42.8 F42.9
ICD9CM 35 300.3
MeSH 44 D009771
NCIt 50 C88411
SNOMED-CT 68 71478004
MedGen 42 C0028768
KEGG 37 H01450
Sources

Summaries for Obsessive-Compulsive Disorder

About this section
MedlinePlus : 43 Obsessive-compulsive disorder (OCD) is a type of anxiety disorder. If you have OCD, you have frequent, upsetting thoughts called obsessions. To try to control the thoughts, you feel an overwhelming urge to repeat certain rituals or behaviors. These are called compulsions. Examples of obsessions are a fear of germs or a fear of being hurt. Compulsions include washing your hands, counting, checking on things, or cleaning. With OCD, the thoughts and rituals cause distress and get in the way of your daily life. Researchers think brain circuits may not work properly in people who have OCD. It tends to run in families. The symptoms often begin in children or teens. Treatments include therapy, medicines, or both. One type of therapy, cognitive behavioral therapy, is useful for treating OCD. NIH: National Institute of Mental Health

MalaCards based summary : Obsessive-Compulsive Disorder, also known as ocd, is related to trichotillomania and autism spectrum disorder, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Obsessive-Compulsive Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Serotonergic synapse and Dopaminergic synapse. The drugs Citalopram and Fluvoxamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are depressivity and anxiety

Disease Ontology : 12 An anxiety disorder that involves unwanted and repeated thoughts, feelings, ideas, sensations (obsessions), or behaviors that make them feel driven to do something (compulsions).

Genetics Home Reference : 25 Obsessive-compulsive disorder (OCD) is a mental health condition characterized by features called obsessions and compulsions. Obsessions are intrusive thoughts, mental images, or urges to perform specific actions. While the particular obsessions vary widely, they often include fear of illness or contamination; a desire for symmetry or getting things "just right;" or intrusive thoughts involving religion, sex, or aggression. Compulsions consist of the repetitive performance of certain actions, such as checking or verifying, washing, counting, arranging, acting out specific routines, or seeking assurance. These behaviors are performed to relieve anxiety, rather than to seek pleasure as in other compulsive behaviors like gambling, eating, or sex.

OMIM : 57 Obsessive-compulsive disorder (OCD) is characterized by recurring obsessions and/or compulsions and has been estimated to affect nearly 5 million people in the United States (Karno et al., 1988). Evidence for a strong genetic component in OCD comes from twin studies, family genetics studies, and segregation analyses, as reviewed by Alsobrook et al. (2002). Zhang et al. (2002) suggested that hoarding is likely to be an evolutionarily conserved trait that, in times of adversity, was associated with increased survival and reproductive fitness. However, extreme forms of this trait are associated with marked disability and poor response to treatment (Black et al., 1998; Mataix-Cols et al., 1999). (164230)

PubMed Health : 63 About obsessive-compulsive disorder: We all know the worrying feeling that we have forgotten to do something, like turning off the oven or locking the door. And it might be a good idea to double-check if you aren't absolutely sure. But some people are so worried about forgetting to do something that they feel the urge to check over and over again. Compulsive urges like this may gradually come to dominate their whole life. There are different types of obsessive-compulsive disorder (OCD). Some people are so afraid of germs that they constantly wash their hands. Others can't stop counting things, cleaning their surroundings or obsessing over the same repetitive thoughts. Regardless of the kind of ritual they may have developed, people who have OCD just can't stop doing these things.

Wikipedia : 76 Obsessive�??compulsive disorder (OCD) is a mental disorder where people feel the need to check things... more...

Sources

Related Diseases for Obsessive-Compulsive Disorder

About this section

Diseases related to Obsessive-Compulsive Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 trichotillomania 32.8 DLGAP3 SLITRK1
2 autism spectrum disorder 32.8 BDNF HTR2A SLC6A4 TPH2
3 gilles de la tourette syndrome 32.5 BDNF COMT DRD2 DRD4 HTR3A SGCE
4 anxiety 32.5 BDNF COMT HTR1A HTR2A HTR2C HTR3A
5 depression 31.5 BDNF HTR1A HTR2A HTR2C MAOA SLC6A4
6 anorexia nervosa 31.4 BDNF COMT HTR2A SLC6A4
7 tic disorder 31.4 DRD2 DRD4 HTR2A SLC6A3 SLITRK1 TPH2
8 agoraphobia 31.3 HTR1A MAOA SLC6A4
9 alexithymia 31.3 COMT DRD2 HTR1A SLC6A4
10 generalized anxiety disorder 31.2 BDNF COMT DRD2 HTR1A HTR2A HTR3A
11 social phobia 31.1 DRD2 HTR1A HTR3A MAOA SLC6A4
12 pathological gambling 31.1 DRD2 DRD4 HTR2A MAOA SLC6A3 SLC6A4
13 panic disorder 31.1 BDNF COMT HTR1A HTR2A HTR2C HTR3A
14 personality disorder 31.1 BDNF COMT DRD2 DRD4 HTR1A HTR1B
15 eating disorder 31.1 BDNF COMT DRD2 HTR2C SLC6A3 SLC6A4
16 autism 31.0 BDNF COMT DRD2 DRD4 HTR1A HTR2A
17 schizoaffective disorder 30.9 BDNF COMT DRD2 HTR2A SLC1A1 SLC6A4
18 kleptomania 30.8 HTR1A MAOA SLC6A4 SLITRK1
19 asperger syndrome 30.8 BDNF SGCE SLC6A4
20 schizophrenia 30.8 TPH2 SLC6A4 SLC6A3 SLC1A1 MAOA HTR3A
21 post-traumatic stress disorder 30.8 BDNF COMT DRD2 HTR2A MAOA SLC6A4
22 temporal lobe epilepsy 30.8 BDNF HTR1A SLC1A1
23 dysthymic disorder 30.8 HTR2A MAOA SLC6A4
24 endogenous depression 30.8 BDNF HTR1A HTR2A MAOA SLC6A4
25 early-onset schizophrenia 30.8 BDNF DRD2 HTR2A
26 movement disease 30.7 DRD2 SGCE SLC6A3
27 brain injury 30.7 BDNF COMT DRD2
28 bipolar disorder 30.7 BDNF COMT DRD2 DRD4 HTR1A HTR2A
29 bulimia nervosa 30.7 BDNF COMT HTR1B HTR2A HTR3A SLC6A4
30 bipolar i disorder 30.7 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
31 conduct disorder 30.5 COMT DRD2 DRD4 MAOA SLC6A3 SLC6A4
32 avoidant personality disorder 30.5 MAOA SLC6A4
33 phobia, specific 30.5 COMT MAOA
34 traumatic brain injury 30.5 BDNF COMT DRD2
35 drug dependence 30.5 BDNF DRD2 SLC6A4
36 mental depression 30.4 BDNF COMT HTR1A HTR2A HTR2C MAOA
37 mood disorder 30.4 BDNF COMT DRD2 DRD4 HTR1A HTR1B
38 alcohol abuse 30.4 BDNF DRD2 DRD4 HTR2A SLC6A4
39 major depressive disorder 30.4 BDNF COMT DRD2 DRD4 HTR1A HTR1B
40 serotonin syndrome 30.3 HTR1A HTR2A HTR3A MAOA SLC6A4
41 paranoid schizophrenia 30.3 BDNF COMT HTR2A MAOA SLC6A4 TPH2
42 psychotic disorder 30.2 BDNF COMT DRD2 DRD4 HTR1A HTR2A
43 attention deficit-hyperactivity disorder 30.0 TPH2 SLC6A4 SLC6A3 MAOA HTR2C HTR2A
44 borderline personality disorder 30.0 BDNF COMT HTR1A HTR1B HTR2A HTR2C
45 disease of mental health 29.9 BDNF COMT DRD2 DRD4 HTR1A HTR2A
46 alcohol dependence 29.8 SLC6A3 SLC6A4 TPH2 MAOA HTR3A HTR2C
47 osteochondritis dissecans 12.0
48 pediatric acute-onset neuropsychiatric syndrome 11.6
49 pediatric autoimmune neuropsychiatric disorders associated with streptococcus infections 11.4
50 dystonia, dopa-responsive 11.3

Comorbidity relations with Obsessive-Compulsive Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Personality Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Disorder:



Diseases related to Obsessive-Compulsive Disorder
Sources

Symptoms & Phenotypes for Obsessive-Compulsive Disorder

About this section

Symptoms via clinical synopsis from OMIM:

57
Neuro:
obsessive-compulsive disorder


Clinical features from OMIM:

164230

Human phenotypes related to Obsessive-Compulsive Disorder:

32
# Description HPO Frequency HPO Source Accession
1 depressivity 32 HP:0000716
2 anxiety 32 HP:0000739
3 obsessive-compulsive behavior 32 obligate (100%) HP:0000722
4 collectionism 32 HP:0030212
5 skin-picking 32 HP:0012166

UMLS symptoms related to Obsessive-Compulsive Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, psychiatric symptom

GenomeRNAi Phenotypes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Obsessive-Compulsive Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 BDNF COMT DLGAP3 DRD2 DRD4 HTR1A
2 homeostasis/metabolism MP:0005376 10.13 BDNF COMT DRD2 DRD4 HTR1A HTR2C
3 endocrine/exocrine gland MP:0005379 10.02 BDNF COMT DRD2 HTR1B HTR2A HTR3A
4 integument MP:0010771 9.86 BDNF DLGAP3 DRD2 HTR2C HTR3A SLC6A3
5 nervous system MP:0003631 9.86 BDNF CDK20 COMT DLGAP3 DRD2 DRD4
6 muscle MP:0005369 9.76 DRD2 HTR1B HTR2A HTR2C HTR3A SGCE
7 taste/olfaction MP:0005394 8.92 BDNF DRD2 SLC6A3 TPH2
Sources

Drugs & Therapeutics for Obsessive-Compulsive Disorder

About this section

PubMedHealth treatment related to Obsessive-Compulsive Disorder: 63

Although there's no “cure” for OCD, with good professional help the symptoms can be reduced to a tolerable level, enabling people with OCD to start leading normal lives again.People with OCD are usually advised to have psychological treatment. Cognitive behavioral therapy (CBT) in particular has been proven to be an effective treatment for OCD. In Germany, it is offered by behavioral therapists (in German: Verhaltenstherapeuten).Medication for depression (antidepressants) may be considered in addition to CBT, or if psychological treatment isn't an option (yet). Selective serotonin re-uptake inhibitors (SSRIs) are commonly used for this purpose.Apart from these treatments, self-help is an option, for example by talking to other people with OCD in a support group. Some people like to use books or websites to learn about their obsessive-compulsive behaviors and deal with them. Others may try to manage their OCD using relaxation techniques like meditation or autogenic training.

Drugs for Obsessive-Compulsive Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 3,Phase 2,Not Applicable 59729-33-8 2771
2
Fluvoxamine Approved, Investigational Phase 4,Phase 3,Not Applicable 54739-18-3 3404 5324346
3
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 61869-08-7 43815
4
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 51-61-6, 62-31-7 681
5
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
6
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 54910-89-3 3386
7
Clomipramine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 303-49-1 2801
8
Cycloserine Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-41-7 6234 401
9
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
10
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
11
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
12
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
13
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79617-96-2 68617
14
Haloperidol Approved Phase 4 52-86-8 3559
15
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
16
Methylphenidate Approved, Investigational Phase 4,Phase 2,Not Applicable 113-45-1 4158
17
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
18
Acamprosate Approved, Investigational Phase 4,Phase 2 77337-76-9 71158
19
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
20
Clonidine Approved Phase 4 4205-90-7 2803
21 Piracetam Approved, Investigational Phase 4,Phase 2,Phase 3 7491-74-9
22
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
23
Propranolol Approved, Investigational Phase 4 525-66-6 4946
24 Etiracetam Investigational Phase 4,Phase 2,Phase 3 33996-58-6
25
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
26 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
29 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Parasympatholytics Phase 4,Phase 3,Phase 2,Not Applicable
38 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
41 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Not Applicable
44 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3,Not Applicable
45 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
46 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Duloxetine Hydrochloride Phase 4,Not Applicable
48 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
49 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4,Phase 3,Not Applicable
50 Analgesics Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 466)
# Name Status NCT ID Phase Drugs
1 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
4 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
5 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
6 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
7 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
8 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
9 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
10 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
11 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
12 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
13 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
14 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
15 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
16 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
17 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
18 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
19 Escitalopram in Schizophrenia in OCD- Open Label Study Completed NCT00456937 Phase 4 Escitalopram
20 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
21 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Completed NCT01339858 Phase 4 N-Acetyl Cysteine
22 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
23 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
24 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
25 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
26 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
27 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
28 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
29 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
30 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
31 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
32 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
33 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
34 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Not yet recruiting NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
35 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
36 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
37 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
38 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
39 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder Unknown status NCT02590445 Phase 2, Phase 3
40 Safety and Effectiveness of Capsulotomy in Refractory OCD Unknown status NCT02375152 Phase 2, Phase 3
41 Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Unknown status NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
42 A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
43 Comparison of DBS Targets in Obsessive-compulsive Disorder Completed NCT01807403 Phase 3
44 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
45 Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
46 A Controlled Trial of Daily Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder Completed NCT00369642 Phase 3
47 Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed NCT00000384 Phase 3 Sertraline
48 D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD) Completed NCT01411774 Phase 3 d-cycloserine;Pill placebo
49 Tolerability and Efficacy of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder (OCD) Completed NCT00305500 Phase 3 escitalopram
50 Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder Completed NCT00533806 Phase 3

Search NIH Clinical Center for Obsessive-Compulsive Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: obsessive-compulsive disorder

Sources

Genetic Tests for Obsessive-Compulsive Disorder

About this section

Genetic tests related to Obsessive-Compulsive Disorder:

# Genetic test Affiliating Genes
1 Obsessive-Compulsive Disorder 29 HTR2A SLC6A4
Sources

Anatomical Context for Obsessive-Compulsive Disorder

About this section

MalaCards organs/tissues related to Obsessive-Compulsive Disorder:

41
Brain, Testes, Cortex, Skin, Subthalamic Nucleus, Prefrontal Cortex, Thalamus
Sources

Publications for Obsessive-Compulsive Disorder

About this section

Articles related to Obsessive-Compulsive Disorder:

(show top 50) (show all 3009)
# Title Authors Year
1
Corrigendum to "Implicit aggressiveness self-concepts in patients with obsessive-compulsive disorder as assessed by an implicit associations test" [Journal of Behavior Therapy and Experimental Psychiatry 55 (June 2017) 106-112]. ( 30017336 )
2019
2
Labour market marginalisation in obsessive-compulsive disorder: a nationwide register-based sibling control study. ( 29950186 )
2018
3
Progress and challenges in deep brain stimulation for obsessive-compulsive disorder. ( 29406245 )
2018
4
Adding acceptance and commitment therapy to exposure and response prevention for obsessive-compulsive disorder: A randomized controlled trial. ( 29966992 )
2018
5
Obsessive-compulsive symptoms in children with first degree relatives diagnosed with obsessive-compulsive disorder. ( 29898190 )
2018
6
Augmentation Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation Over Presupplementary Motor Area in Obsessive-Compulsive Disorder: A Randomized Controlled Trial. ( 29901496 )
2018
7
Social Support and Symptom Severity Among Patients With Obsessive-Compulsive Disorder or Panic Disorder With Agoraphobia: A Systematic Review. ( 29899808 )
2018
8
Subthalamic theta activity: a novel human subcortical biomarker for obsessive compulsive disorder. ( 29915200 )
2018
9
Mindfulness-based cognitive therapy for obsessive-compulsive disorder: Study protocol for a randomized controlled trial with functional magnetic resonance imaging and a 6-month follow-up. ( 29974808 )
2018
10
Significant concordance of genetic variation that increases both the risk for obsessive-compulsive disorder and the volumes of the nucleus accumbens and putamen. ( 29947313 )
2018
11
Treatment-Refractory Obsessive-Compulsive Disorder in Adults: A Cost-Effectiveness Analysis of Treatment Strategies. ( 29419948 )
2018
12
Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York. ( 29937263 )
2018
13
Internet-delivered cognitive behavioural therapy for young children with obsessive-compulsive disorder: development and initial evaluation of the BIP OCD Junior programme. ( 29971153 )
2018
14
The detection of white matter alterations in obsessive-compulsive disorder revealed by TRActs Constrained by UnderLying Anatomy (TRACULA). ( 29950845 )
2018
15
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
16
The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). ( 29930930 )
2018
17
Assessing Acute Secondary Treatment Outcomes in Early-Onset Obsessive-Compulsive Disorder. ( 29435695 )
2018
18
A network perspective on comorbid depression in adolescents with obsessive-compulsive disorder. ( 29125957 )
2018
19
Oral N-acetylcysteine in the treatment of obsessive-compulsive disorder: A systematic review of the clinical evidence. ( 29908912 )
2018
20
Association between glutamate transporter gene polymorphisms and obsessive-compulsive disorder/trait empathy in a Korean population. ( 29304071 )
2018
21
Pharmacogenetic evaluation of a DISP1 gene variant in antidepressant treatment of obsessive-compulsive disorder. ( 29953682 )
2018
22
Suicide risk in Obsessive-Compulsive Disorder and exploration of risk factors: a systematic review. ( 29929465 )
2018
23
Lost in translation? A critical look at the role that animal models of obsessive compulsive disorder play in current drug discovery strategies. ( 29275640 )
2018
24
Pituitary gland volumes in patients with obsessive-compulsive disorder before and after cognitive-behavioral therapy. ( 29898196 )
2018
25
Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder. ( 29394511 )
2018
26
8-F2-isoprostane, thioredoxin and thioredoxin reductase levels in children with obsessive-compulsive disorder. ( 29927677 )
2018
27
Eveningness is associated with poor sleep quality and negative affect in obsessive-compulsive disorder. ( 29415552 )
2018
28
Safety of Transcranial Magnetic Stimulation in an Obsessive-Compulsive Disorder Patient With Deep Brain Stimulation: A Case Report. ( 29952858 )
2018
29
The relationship between theory of mind and insight in obsessive-compulsive disorder. ( 29426262 )
2018
30
White Matter Features Associated With Autistic Traits in Obsessive-Compulsive Disorder. ( 29896127 )
2018
31
Obsessive-compulsive disorder after therapy for an optic pathway glioma. ( 29556577 )
2018
32
Increased Default Mode Network Connectivity in Obsessive-Compulsive Disorder During Reward Processing. ( 29951007 )
2018
33
Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder. ( 29440404 )
2018
34
The temporal relationship between premonitory urges and covert compulsions in patients with obsessive-compulsive disorder. ( 29407570 )
2018
35
A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD). ( 29423665 )
2018
36
Altered Functional Connectivity of the Default Mode Network in Patients With Schizo-obsessive Comorbidity: A Comparison Between Schizophrenia and Obsessive-compulsive Disorder. ( 29365198 )
2018
37
A Case of Obsessive-Compulsive Disorder Comorbid with Miyoshi Myopathy. ( 29403136 )
2018
38
Neurological soft signs, dissociation and alexithymia in patients with obsessive-compulsive disorder (OCD) and healthy subjects. ( 29175504 )
2018
39
Genetic variability in the serotoninergic system and age of onset in anorexia nervosa and obsessive-compulsive disorder. ( 30554102 )
2018
40
Successful use of electroconvulsive therapy in a patient with anorexia nervosa and severe acute-onset obsessive-compulsive disorder. ( 30051497 )
2018
41
Examination of the shared genetic basis of anorexia nervosa and obsessive-compulsive disorder. ( 30087453 )
2018
42
Associations between dimensions of anorexia nervosa and obsessive-compulsive disorder: An examination of personality and psychological factors in patients with anorexia nervosa. ( 30136346 )
2018
43
Choosing the appropriate pharmacotherapy for obsessive-compulsive disorder in adult patients with comorbid anxiety disorders: clinical and nosological considerations. ( 30496694 )
2018
44
Duration of untreated illness in a cross-diagnostic sample of obsessive-compulsive disorder, panic disorder, and social anxiety disorder. ( 30419984 )
2018
45
A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive-compulsive disorder: Mapping the way forward. ( 30361863 )
2018
46
Cognitive performance of youth with primary generalized anxiety disorder versus primary obsessive-compulsive disorder. ( 30375085 )
2018
47
Possible Sertraline-Induced Hiccups in a Boy With Obsessive-Compulsive Disorder and Attention-Deficit/Hyperactivity Disorder. ( 30398989 )
2018
48
Frontostriatal Dysfunction During Decision Making in Attention-Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder. ( 29706587 )
2018
49
Frontostriatal functional connectivity correlates with repetitive behaviour across autism spectrum disorder and obsessive-compulsive disorder. ( 30362446 )
2018
50
Autism Spectrum Symptoms in Children and Adolescents with Obsessive Compulsive Disorder and Their Mothers. ( 30042640 )
2018
Sources

Variations for Obsessive-Compulsive Disorder

About this section

ClinVar genetic disease variations for Obsessive-Compulsive Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SLC6A4 NM_001045.5(SLC6A4): c.1273A> G (p.Ile425Val) single nucleotide variant risk factor rs28914832 GRCh37 Chromosome 17, 28538374: 28538374
2 SLC6A4 NM_001045.5(SLC6A4): c.1273A> G (p.Ile425Val) single nucleotide variant risk factor rs28914832 GRCh38 Chromosome 17, 30211356: 30211356
3 HTR2A HTR2A, -1438G-A single nucleotide variant risk factor
4 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh37 Chromosome 6, 12124117: 12124117
5 HIVEP1 NM_002114.3(HIVEP1): c.4089G> C (p.Met1363Ile) single nucleotide variant Pathogenic rs776300630 GRCh38 Chromosome 6, 12123884: 12123884
6 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh37 Chromosome 9, 90584834: 90584834
7 CDK20 NM_001039803.2(CDK20): c.564G> A (p.Trp188Ter) single nucleotide variant Pathogenic rs1057519438 GRCh38 Chromosome 9, 87969919: 87969919

Copy number variations for Obsessive-Compulsive Disorder from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 77765 13 47471310 47471410 Deletion Obsessive-compulsive disorder
2 160222 22 11800000 24300000 Deletion Obsessive-compulsive disorder
Sources

Expression for Obsessive-Compulsive Disorder

About this section
Search GEO for disease gene expression data for Obsessive-Compulsive Disorder.
Sources

Pathways for Obsessive-Compulsive Disorder

About this section

Pathways related to Obsessive-Compulsive Disorder according to KEGG:

37
# Name Kegg Source Accession
1 Serotonergic synapse hsa04726
2 Dopaminergic synapse hsa04728
3 Glutamatergic synapse hsa04724

Pathways related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Circadian entrainment 37
Show member pathways
 12.8 COMT DRD2 DRD4 MAOA SLC1A1 SLC6A3
2
Transmission across Chemical Synapses 66
Show member pathways
 12.76 COMT DLGAP3 MAOA SLC1A1 SLC6A3 SLC6A4
3
Neuroscience 4
12.4 COMT HTR1A SLC1A1 TPH2
5
cAMP signaling pathway 37
Show member pathways
 12.08 BDNF DRD2 HTR1A HTR1B
6
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.91 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
7
Taste transduction 37
Show member pathways
 11.82 HTR1A HTR1B HTR3A
8
Monoamine GPCRs 1
Show member pathways
 11.79 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
9
Amphetamine addiction 37
Show member pathways
 11.77 BDNF DRD2 MAOA SLC6A3
10
Gap junction 37
11.63 DRD2 HTR2A HTR2C
11
Serotonergic synapse 37
11.62 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
12
Monoamine Transport 1
Show member pathways
 11.3 MAOA SLC6A3 SLC6A4 TPH2
13
Neurotransmitter Clearance In The Synaptic Cleft 66
Show member pathways
 11.04 COMT MAOA SLC6A3 SLC6A4
14
Biogenic Amine Synthesis 1
Show member pathways
 10.92 COMT MAOA
15
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling 1
10.85 HTR2A HTR2C
16
noradrenaline and adrenaline degradation 1
Show member pathways
 10.71 COMT MAOA
17
Dopamine metabolism 1
10.67 COMT MAOA
18
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 61
10.67 HTR1A HTR1B HTR2A HTR2C HTR3A MAOA
Sources

GO Terms for Obsessive-Compulsive Disorder

About this section

Cellular components related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.85 BDNF COMT DRD2 HTR2A HTR3A SLC6A3
2 glutamatergic synapse GO:0098978 9.8 DLGAP3 DRD2 DRD4 HTR2A HTR3A SLITRK1
3 dendrite GO:0030425 9.61 BDNF COMT DRD2 DRD4 HTR1A HTR1B
4 integral component of postsynaptic membrane GO:0099055 9.55 DRD2 HTR2A HTR3A SLC6A3 SLC6A4
5 dopaminergic synapse GO:0098691 9.48 DRD2 SLC6A3
6 serotonergic synapse GO:0099154 9.4 HTR1B SLC6A4
7 integral component of presynaptic membrane GO:0099056 9.1 DRD2 HTR1B HTR2A HTR3A SLC6A3 SLC6A4
8 membrane GO:0016020 10.37 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B
9 integral component of membrane GO:0016021 10.3 COMT DRD2 DRD4 HTR1A HTR1B HTR2A
10 plasma membrane GO:0005886 10.28 COMT DLGAP3 DRD2 DRD4 HTR1A HTR1B
11 integral component of plasma membrane GO:0005887 10 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C

Biological processes related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.87 COMT DRD2 HTR1B HTR2A HTR2C SLC6A3
2 cellular calcium ion homeostasis GO:0006874 9.85 DRD4 HTR2A HTR2C
3 locomotory behavior GO:0007626 9.85 DRD2 HTR2C SLC6A3
4 response to ethanol GO:0045471 9.85 DRD2 HTR1B HTR3A SLC6A3
5 memory GO:0007613 9.84 BDNF HTR2A SLC6A4
6 synapse assembly GO:0007416 9.79 BDNF DRD2 SLITRK1
7 regulation of synaptic vesicle exocytosis GO:2000300 9.79 DRD2 HTR1B HTR2A
8 release of sequestered calcium ion into cytosol GO:0051209 9.77 DRD2 HTR2A HTR2C
9 feeding behavior GO:0007631 9.74 DRD2 HTR1B HTR2C
10 behavioral fear response GO:0001662 9.73 DRD4 HTR1A HTR2C
11 response to cocaine GO:0042220 9.71 DRD2 HTR1B HTR3A SLC6A3
12 behavioral response to cocaine GO:0048148 9.7 DRD2 DRD4 HTR2A
13 chemical synaptic transmission GO:0007268 9.7 DRD4 HTR1A HTR1B HTR2A HTR2C HTR3A
14 temperature homeostasis GO:0001659 9.69 DRD2 HTR2A
15 positive regulation of kinase activity GO:0033674 9.69 DRD4 HTR2A
16 dopamine receptor signaling pathway GO:0007212 9.69 DRD2 DRD4
17 vasoconstriction GO:0042310 9.69 HTR1A HTR1B SLC6A4
18 negative regulation of protein secretion GO:0050709 9.68 DRD2 DRD4
19 response to iron ion GO:0010039 9.68 DRD2 SLC6A3
20 prepulse inhibition GO:0060134 9.68 DRD2 SLC6A3
21 neurotransmitter biosynthetic process GO:0042136 9.67 SLC6A3 SLC6A4
22 G protein-coupled receptor internalization GO:0002031 9.67 DRD2 HTR1B
23 dopamine metabolic process GO:0042417 9.67 COMT DRD2 DRD4
24 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.67 DRD4 HTR1A HTR1B HTR2A
25 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.66 DRD2 DRD4
26 catecholamine metabolic process GO:0006584 9.65 COMT MAOA
27 neurotransmitter catabolic process GO:0042135 9.65 COMT MAOA
28 regulation of behavior GO:0050795 9.65 HTR1A HTR1B
29 regulation of dopamine metabolic process GO:0042053 9.65 DRD4 HTR1A SLC6A3
30 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.65 DRD4 HTR1A HTR1B HTR2A HTR2C
31 adenohypophysis development GO:0021984 9.64 DRD2 SLC6A3
32 behavioral response to ethanol GO:0048149 9.64 DRD2 DRD4
33 monoamine transport GO:0015844 9.63 SLC6A3 SLC6A4
34 negative regulation of voltage-gated calcium channel activity GO:1901386 9.63 DRD2 DRD4
35 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.63 DRD2 HTR1B HTR2A
36 drinking behavior GO:0042756 9.62 DRD2 HTR1B
37 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.61 HTR2A HTR2C
38 dopamine catabolic process GO:0042420 9.61 COMT MAOA SLC6A3
39 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.59 HTR1A HTR1B
40 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.58 DRD2 DRD4
41 response to histamine GO:0034776 9.58 DRD2 DRD4
42 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.54 HTR2A HTR2C
43 behavior GO:0007610 9.26 HTR1A HTR1B HTR2A HTR2C
44 serotonin receptor signaling pathway GO:0007210 8.92 HTR1A HTR2A HTR2C HTR3A

Molecular functions related to Obsessive-Compulsive Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.95 DRD2 DRD4 HTR1A HTR1B HTR2A HTR2C
2 symporter activity GO:0015293 9.69 SLC1A1 SLC6A3 SLC6A4
3 neurotransmitter receptor activity GO:0030594 9.65 DRD4 HTR1A HTR1B HTR2A HTR2C
4 G protein-coupled serotonin receptor activity GO:0004993 9.55 DRD4 HTR1A HTR1B HTR2A HTR2C
5 dopamine binding GO:0035240 9.5 DRD2 DRD4 SLC6A3
6 neurotransmitter:sodium symporter activity GO:0005328 9.49 SLC6A3 SLC6A4
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.46 DRD2 DRD4
8 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC6A4
9 drug binding GO:0008144 9.43 DRD2 DRD4 HTR1B HTR2A HTR2C SLC6A3
10 dopamine neurotransmitter receptor activity GO:0004952 9.4 DRD2 DRD4
11 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.37 HTR2A HTR2C
12 serotonin binding GO:0051378 9.1 HTR1A HTR1B HTR2A HTR2C HTR3A SLC6A4
Sources

Sources for Obsessive-Compulsive Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....